Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Longikaurin A is a natural ent-kaurane diterpenoid isolated from the medicinal plant *Isodon ternifolius*. It exhibits potent anti-cancer properties, specifically demonstrated in models of hepatocellular carcinoma (HCC). The compound's mechanism of action involves inducing G2/M phase cell cycle arrest by downregulating the E3 ubiquitin ligase S-phase kinase-associated protein 2 (Skp2), which subsequently leads to the stabilization and increased expression of the cyclin-dependent kinase inhibitor p21. Additionally, Longikaurin A triggers apoptosis through the accumulation of reactive oxygen species (ROS), which activates the JNK/c-Jun signaling pathway. Preclinical studies in SMMC-7721 xenograft models have shown significant tumor suppression with minimal organ-related toxicity, positioning it as a promising lead compound for the development of targeted liver cancer therapies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on longikaurin a.